292 related articles for article (PubMed ID: 34724412)
1. Polycystic Liver Disease: Advances in Understanding and Treatment.
Masyuk TV; Masyuk AI; LaRusso NF
Annu Rev Pathol; 2022 Jan; 17():251-269. PubMed ID: 34724412
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targets in Polycystic Liver Disease.
Masyuk TV; Masyuk AI; LaRusso NF
Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
[TBL] [Abstract][Full Text] [Related]
3. Clinical manifestation, epidemiology, genetic basis, potential molecular targets, and current treatment of polycystic liver disease.
Mahboobipour AA; Ala M; Safdari Lord J; Yaghoobi A
Orphanet J Rare Dis; 2024 Apr; 19(1):175. PubMed ID: 38671465
[TBL] [Abstract][Full Text] [Related]
4. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
[TBL] [Abstract][Full Text] [Related]
5. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
[TBL] [Abstract][Full Text] [Related]
6. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Santos-Laso A; Azkargorta M; Elortza F; Martinez-Chantar ML; Perugorria MJ; Aspichueta P; Marzioni M; LaRusso NF; Bujanda L; Drenth JPH; Banales JM
J Hepatol; 2021 Feb; 74(2):394-406. PubMed ID: 32950589
[TBL] [Abstract][Full Text] [Related]
7. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.
Barten TRM; Bernts LHP; Drenth JPH; Gevers TJG
Expert Opin Ther Targets; 2020 Jun; 24(6):589-599. PubMed ID: 32250187
[No Abstract] [Full Text] [Related]
8. Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease.
Ji R; Chen J; Xie Y; Dou X; Qing B; Liu Z; Lu Y; Dang L; Zhu X; Sun Y; Zheng X; Zhang L; Guo D; Chen Y
J Hepatol; 2023 Apr; 78(4):754-769. PubMed ID: 36681161
[TBL] [Abstract][Full Text] [Related]
9. Polycystic liver diseases: congenital disorders of cholangiocyte signaling.
Strazzabosco M; Somlo S
Gastroenterology; 2011 Jun; 140(7):1855-9, 1859.e1. PubMed ID: 21515270
[TBL] [Abstract][Full Text] [Related]
10. An update on the pathophysiology and management of polycystic liver disease.
Wong MY; McCaughan GW; Strasser SI
Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):569-581. PubMed ID: 28317394
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Perugorria MJ; Azkargorta M; Elortza F; Martinez-Chantar ML; Aspichueta P; Marzioni M; Bujanda L; Drenth JPH; Banales JM
United European Gastroenterol J; 2021 Sep; 9(7):848-859. PubMed ID: 34310849
[TBL] [Abstract][Full Text] [Related]
12. Somatic second-hit mutations leads to polycystic liver diseases.
Banales JM; Munoz-Garrido P; Bujanda L
World J Gastroenterol; 2013 Jan; 19(1):141-3. PubMed ID: 23326178
[TBL] [Abstract][Full Text] [Related]
13. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management.
Cnossen WR; Drenth JP
Orphanet J Rare Dis; 2014 May; 9():69. PubMed ID: 24886261
[TBL] [Abstract][Full Text] [Related]
14. TGR5 in the Cholangiociliopathies.
Masyuk TV; Masyuk AI; LaRusso NF
Dig Dis; 2015; 33(3):420-5. PubMed ID: 26045278
[TBL] [Abstract][Full Text] [Related]
15. Genetics and mechanisms of hepatic cystogenesis.
van de Laarschot LFM; Drenth JPH
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1491-1497. PubMed ID: 28782656
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and management of polycystic liver disease.
Gevers TJ; Drenth JP
Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):101-8. PubMed ID: 23296249
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.
Abu-Wasel B; Walsh C; Keough V; Molinari M
World J Gastroenterol; 2013 Sep; 19(35):5775-86. PubMed ID: 24124322
[TBL] [Abstract][Full Text] [Related]
18. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]